Department of Error

Lancet (London, England) · 2022 · vol. 400(10353) , pp. 660 · doi:10.1016/s0140-6736(22)01581-1 · PMID:36030810 · W4293216478
Other OA: hybrid CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-16 ⓘ

The SPIRIT 1 and 2 phase 3 trials investigated daily oral relugolix combination therapy for endometriosis-associated pain, with a correction made to a table reference in the published results.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Guidice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet 2022; 399: 2267–79—In this Article, the sixth sentence of the third paragraph of the Results section should have referenced table 2 (not table 3). This correction has been made to the online version as of Aug 25, 2022.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:36:33.795939+00:00
License: CC0 · commercial use OK